01Precision BioSciences reported Q3 2026 EPS of -$0.28, beating estimates by $0.64 per share, but revenue missed expectations.
02The company's stock trades at $7.09 with a market cap of $65.0M following the November 3, 2026 earnings release.
03Q3 marked a significant improvement from Q2's -$1.26 EPS miss of -85.3%, suggesting recent operational changes.
04The 70% earnings beat is substantially larger than typical surprises and may prompt analyst estimate revisions.
Earnings Results
Precision BioSciences (NASDAQ:DTIL) reported quarterly earnings results on November 03, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.28, beating the consensus estimate of $-0.92 by $0.64 per share. Revenue came in at , missing the estimate of $1.4M.
Company Overview
Precision BioSciences's stock moved following the earnings release. The stock currently trades at $7.09 with a market capitalization of $65.0M.
Precision BioSciences's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 70% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Precision BioSciences should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.